The ‘don’t eat me’ an­ti­dote: Glax­o­SmithK­line, Roche and No­vo back $86M start­up in high-stakes CD47 show­down

CD47 is a hot prospect in the im­muno-on­col­o­gy world. And Wash­ing­ton Uni­ver­si­ty spin­out Tioma Ther­a­peu­tics plans to be a play­er in that boom­ing R&D game.

It’s an old­er start­up, seed­ed for years to cov­er pre­clin­i­cal work but now prep­ping for a turn in the clin­i­cal spot­light. To­day the com­pa­ny land­ed an $86 mil­lion launch round and an ex­pe­ri­enced biotech hand who is now at the helm. River­Vest Ven­ture Part­ners co-led the round along with a trio of phar­ma heavy­weights: No­vo Ven­tures, Roche Ven­ture Fund and Glax­o­SmithK­line’s S.R. One.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.